Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies
Iranian Journal of Pharmaceutical Research · 29.10.2024 · 23 (1)
DOI: 10.5812/ijpr-151581 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 29.10.2024. Verfasst von Maryam Bayanati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food Technology Research, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology,…. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Dipeptidyl peptidase 4 (DPP-4) is a serine exopeptidase enzyme that hydrolyzes the amide bond at the N-terminal of peptides. This enzyme converts incretins, such as glucagon-like peptide I and glucose-dependent insulinotropic peptide, into their inactive forms, thereby preventing them from stimulating insulin secretion. Numerous studies have confirmed the role of DPP-4 in the pathophysiology of type 2 diabetes, leading to the development of various DPP-4 inhibitors. In recent years, research on DPP-4 inhibitors has expanded significantly, resulting in the creation of both non-peptidomimetic heterocyclic compounds and peptidomimetic scaffolds. Evidence Acquisition: This systematic review summarizes all recent advances related to DPP-4 inhibitors up to 2024. It begins by outlining the biochemical characteristics of DPP-4 and general pharmacological principles of DPP-4 inhibition, followed by an overview of the latest developments from recent publications. The review provides valuable insights into the pharmacophores necessary for ligand-protein interactions, aimed at understanding the structure-activity relationship of novel DPP-4 inhibitors. Data for this review was collected from sources including ScienceDirect, PubMed, and Scopus.
Results
This review highlights various chemical scaffolds that have been explored in the development of novel DPP-4 inhibitors. It emphasizes scaffolds with significant DPP-4 inhibitory activity, including azoles, azines, sulfonamides, and quinolone motifs. The article also details the structure-activity relationships of newly developed analogs, providing a comprehensive overview of recent advancements in this area.
Conclusions
Despite moderate progress in the development of novel DPP-4 inhibitors, emerging molecular aspects of DPP-4 intervention show great promise for future therapeutic developments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Food Technology Research, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Maryam Bayanati, Elham Rezaee, Sayyed Abbas Tabatabai
Zitieren
APA
Bayanati, M., Ismail Mahboubi Rabbani, M., Sirous Kabiri, S., Mir, B., Rezaee, E., & Tabatabai, S. A. (2024). Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies. Iranian Journal of Pharmaceutical Research, 23(1). https://doi.org/10.5812/ijpr-151581
Vancouver
Bayanati M, Ismail Mahboubi Rabbani M, Sirous Kabiri S, Mir B, Rezaee E, Tabatabai SA. Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies. Iranian Journal of Pharmaceutical Research. 2024;23(1). doi:10.5812/ijpr-151581
BibTeX
@article{Bayanati2024,
author = {Bayanati, Maryam and Ismail Mahboubi Rabbani, Mohammad and Sirous Kabiri, Shirin and Mir, Bahareh and Rezaee, Elham and Tabatabai, Sayyed Abbas},
title = {Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review of Structure-Activity Relationship Studies},
journal = {Iranian Journal of Pharmaceutical Research},
year = {2024},
volume = {23},
number = {1},
doi = {10.5812/ijpr-151581}
}
EUVIMED